FEI and NovAliX Partner to Provide Electron Microscopy-based Structural Biology Services for the Pharmaceutical Industry
March 21 2016 - 7:00AM
FEI (NASDAQ:FEIC) and NovAliX, a contract research organization
(CRO), announced today a strategic partnership to enable NovAliX to
provide commercial cryo-electron microscopy (EM)-based structural
analysis services to its customers in the pharmaceutical and
biotech industry. NovAliX has integrated a cryo-EM workflow based
on a transmission electron microscope (TEM). The collaboration
combines application, training, and support with on-site personnel
from FEI.
“There is a growing demand for structural studies from the
pharmaceutical industry, driven by the need for a deeper scientific
understanding, and also because of stronger regulatory constraints.
In the field of biologics, EM analysis has proven to be capable of
delivering critical information for antibody selection, epitope
mapping and formulation. As for small molecules research programs,
cryo-EM can be uniquely valuable to obtain structural information
on multi-protein complexes or membrane proteins, which is key to
understanding the structure-function relationship,” said Denis
Zeyer, CEO, NovAliX.
TEM-based structural analysis has emerged as an important
complementary technique to traditional methods, such as X-ray
crystallography and nuclear magnetic resonance (NMR). Although TEM
lacks the atomic-scale resolution of those techniques, it can look
at a broader range of structures under conditions much closer to
the native intracellular environment.
Zeyer added, “During the latest NovAliX conference, we have
witnessed the interest and the relevance of biophysical tools in
drug discovery. So, this new offering will nicely complement our
structural biology and biophysical platform that includes X-ray,
NMR, surface plasmon resonance (SPR) and native mass spectrometry
(native MS). Now with cryo-EM available, NovAliX scientists are
able to deliver critical insights into the biology of protein
complexes. Indeed, we will be able to fit X-ray structural results
of individual proteins with a global structural view of the complex
obtained by cryo-EM, which is otherwise not easily accessible.“
Peter Fruhstorfer, vice president and general manager of FEI’s
Life Sciences Business states, “We are extremely pleased to be able
to work with a leading contract research organization like NovAliX.
The power and value of cryo-EM based structural analysis is evident
from the quality of recent publications by academic and industry
researchers. This collaboration with NovAliX is an important step
in the broader commercialization and industrialization of the
technology.”
For more information about FEI’s cryo-EM solutions for biology,
please visit:
http://www.fei.com/life-sciences/structural-biology/.
About NovAliXNovAliX is a privately-owned
organization providing expert driven outsourcing and insourcing
research services for drug discovery. Core expertize includes
synthetic organic chemistry expertise, FBDD and SBDD. The
comprehensive portfolio of biophysical and analytical technologies
include: chemical microarray SPR, native MS, NMR, Biacore, ITC as
well as strong structural biology expertise based on x-ray
crystallography and electron microscopy. More information can be
found at: www.novalix-pharma.com.
NovAliX Conference 2016: Biophysics in Drug Discovery. More
information can be found at http://bit.ly/1RcuaHk.
About FEIFEI Company (Nasdaq:FEIC) designs,
manufactures and supports a broad range of high-performance
microscopy workflow solutions that provide images and answers at
the micro-, nano- and picometer scales. Its innovation and
leadership enable customers in industry and science to increase
productivity and make breakthrough discoveries. Headquartered in
Hillsboro, Ore., USA, FEI has over 2,800 employees and sales and
service operations in more than 50 countries around the world. More
information can be found at: www.fei.com.
FEI Safe Harbor Statement This news release
contains forward-looking statements that include statements
regarding the performance capabilities and benefits of cryo-EM and
the related workflows. Factors that could affect these
forward-looking statements include but are not limited to our
ability to manufacture, ship, deliver and install the tools,
solutions or software as expected; failure of the product or
technology to perform as expected; unexpected technology problems
and challenges; changes to the technology; the inability of FEI,
its suppliers or project partners to make the technological
advances required for the technology to achieve anticipated
results; and the inability of the customer to deploy the tools or
develop and deploy the expected new applications, including the
combination of cyro-EM into other workflows. Please also refer to
our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the
U.S. Securities and Exchange Commission for additional information
on these factors and other factors that could cause actual results
to differ materially from the forward-looking statements. FEI
assumes no duty to update forward-looking statements.
For more information contact:
Sandy Fewkes (media contact)
MindWrite Communications, Inc.
+1 408 224 4024
sandy@mind-write.com
FEI
Jason Willey (investors and analysts)
Sr. Director, Investor Relations & Corporate Development
+1 503 726 2533
jason.willey@fei.com
Fei Company (MM) (NASDAQ:FEIC)
Historical Stock Chart
From Apr 2024 to May 2024
Fei Company (MM) (NASDAQ:FEIC)
Historical Stock Chart
From May 2023 to May 2024